FindTrial
Sign In

The analgesic effect of rTMS targeted activation of DLPFC on bone cancer pain

The study of analgesic effect and mechanism of targeted regulation of prefrontal dorsolateral cortex (DLPFC) on bone cancer pain

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17010817
Enrollment
Unknown
Registered
2017-03-08
Start date
2017-03-21
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone cancer pain

Interventions

control group:rTMS group

Sponsors

Tumor Hospital of Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1) imaging diagnosis of solid tumor bone metastasis or primary bone tumor patients; 2) 0~10 pain rating score (VAS score)=4 points; 3) the age of more than 18 -55 years, life expectancy of more than 3 months; 4) be able to correctly assess pain; 5) informed consent for this study, the voluntary participation in this study.

Exclusion criteria

Exclusion criteria: 1) patients with abnormal brain tumors (tumor, hemorrhage, infarction) were detected by conventional mri; 2) suffering from mental illness such as depression, anxiety and substance abuse; 3) the presence of MRI (with a contraindication to the middle MRI examination); 4) non cancerous pain; 5) alcohol abuse or severe liver disease.

Design outcomes

Primary

MeasureTime frame
VAS score;—

Countries

China

Contacts

Public ContactTang Ying

Tumor Hospital of Chongqing

jm_hou@163.com+86 13452174416

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026